Effect of Dendritic Cell-cytokine-induced Killer Cells in Patients with Advanced Colorectal Cancer Combined with First-line Treatment

Overview

Journal World J Surg Oncol

Publisher Biomed Central

Specialties General Surgery
Oncology

Date 2017 Nov 29

PMID 29179719

Citations 17

Authors

Yunqing Xie

Lijie Huang

Luchuan Chen

Xiaowei Lin

Li Chen

Qiuhong Zheng

Affiliations

Soon will be listed here.

Abstract

Background: Surgical resection combined with adjuvant chemotherapy is considered as the gold-standard treatment for advanced colorectal cancer patients. These patients have a poor 5-year survival rate of 5% or less. Furthermore, a large dose of chemotherapy can produce adverse side effects and severe toxicity. Therefore, this retrospective study aimed to evaluate the efficacy of dendritic cell-cytokine-induced killer (DC-CIK) cell infusion as an adjuvant therapy in patients with advanced colorectal cancer combined with first-line treatment.

Methods: A total of 142 patients with stage III/IV colorectal carcinoma who had been treated with first-line therapy were included in this study. Among these patients, 71 patients received first-line treatment only (non-DC-CIK group), while the other 71 patients who had similar demographic and clinical characteristics received a DC-CIK cell infusion combined with first-line treatment (DC-CIK group). These patients were followed up until August 2014. Data were analyzed by Kaplan-Meier and Cox regression.

Results: Our results showed that the 5-year overall survival (OS) rate for the DC-CIK group versus the non-DC-CIK group was 41.3 versus 19.4% (p = 0.001) and the 5-year progression-free survival (PFS) rate for the DC-CIK group versus the non-DC-CIK group was 57.4 versus 33.6% (p = 0.022).

Conclusions: Our results showed that patients with advanced colorectal cancer might benefit from DC-CIK immunotherapy combined with first-line therapy by significantly prolonging 5-year OS and PFS.

Citing Articles

Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case-control comparative study.

Chang S, Ke T, Chen W, Shyu W, Jeng L Front Immunol. 2024; 15:1329615.

PMID: 38476223 PMC: 10927724. DOI: 10.3389/fimmu.2024.1329615.

Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases.

Li C, Tomita Y, Dhakal B, Tin T, Li R, Wright J Cancer Immunol Immunother. 2024; 73(1):6.

PMID: 38231291 PMC: 10794456. DOI: 10.1007/s00262-023-03591-4.

Safety of dendritic cell and cytokine-induced killer (DC-CIK) cell-based immunotherapy in patients with solid tumor: a retrospective study in China.

Wang S, Song Y, Shi Q, Qiao G, Zhao Y, Zhou L Am J Cancer Res. 2023; 13(10):4767-4782.

PMID: 37970341 PMC: 10636667.

Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review.

Eralp Y, Ates U Vaccines (Basel). 2023; 11(10).

PMID: 37896948 PMC: 10610904. DOI: 10.3390/vaccines11101545.

MMP9-Associated Tumor Stem Cells, CCL1-Silenced Dendritic Cells, and Cytokine-Induced Killer Cells Have a Remarkable Therapeutic Efficacy for Acute Myeloid Leukemia by Activating T Cells.

Dong M, Zhang G, Meng J, Liu B, Jiang D, Liu F Stem Cells Int. 2023; 2023:2490943.

PMID: 37200633 PMC: 10188259. DOI: 10.1155/2023/2490943.

References

Iwai K, Soejima K, Kudoh S, Umezato Y, Kaneko T, Yoshimori K . Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother. 2012; 61(10):1781-90. PMC: 3448049. DOI: 10.1007/s00262-012-1226-4. View

Swartz M . Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res. 2014; 2(8):701-7. DOI: 10.1158/2326-6066.CIR-14-0115. View

Li J, Gu M, Pan K, Liu L, Zhang H, Shen W . Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 2012; 35(2):189-95. DOI: 10.1097/CJI.0b013e318241d9de. View

Frohlich M . Sipuleucel-T for the treatment of advanced prostate cancer. Semin Oncol. 2012; 39(3):245-52. DOI: 10.1053/j.seminoncol.2012.02.004. View

Zhao M, Li H, Li L, Zhang Y . Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med. 2014; 7(5):1403-1407. PMC: 3991503. DOI: 10.3892/etm.2014.1574. View

Sharif S, OConnell M, Yothers G, Lopa S, Wolmark N . FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest. 2008; 26(9):956-63. PMC: 2588473. DOI: 10.1080/07357900802132550. View

Avila M, Berasain C, Sangro B, Prieto J . New therapies for hepatocellular carcinoma. Oncogene. 2006; 25(27):3866-84. DOI: 10.1038/sj.onc.1209550. View

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2012. CA Cancer J Clin. 2012; 62(1):10-29. DOI: 10.3322/caac.20138. View

Tan J, Cang S, Ma Y, Petrillo R, Liu D . Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010; 3:5. PMC: 2827364. DOI: 10.1186/1756-8722-3-5. View

10.

Sargent D, Sobrero A, Grothey A, OConnell M, Buyse M, Andre T . Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009; 27(6):872-7. PMC: 2738431. DOI: 10.1200/JCO.2008.19.5362. View

11.

Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P . Tumor-induced immune dysfunction. Cancer Immunol Immunother. 1999; 48(7):353-62. PMC: 11037211. DOI: 10.1007/s002620050586. View

12.

Ke T, Liao Y, Chiang H, Chang S, Wang P, Chen Y . Effectiveness of neoadjuvant concurrent chemoradiotherapy versus up-front proctectomy in clinical stage II-III rectal cancer: A population-based study. Asia Pac J Clin Oncol. 2014; 12(2):e234-40. DOI: 10.1111/ajco.12172. View

13.

Gao D, Li C, Xie X, Zhao P, Wei X, Sun W . Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 2014; 9(4):e93886. PMC: 3974849. DOI: 10.1371/journal.pone.0093886. View

14.

Su X, Zhang L, Jin L, Ye J, Guan Z, Chen R . Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells. J Clin Immunol. 2010; 30(5):766-74. DOI: 10.1007/s10875-010-9434-1. View

15.

Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf I . Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2010; 137(2):305-10. DOI: 10.1007/s00432-010-0887-7. View

16.

Dudley M, Yang J, Sherry R, Hughes M, Royal R, Kammula U . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26(32):5233-9. PMC: 2652090. DOI: 10.1200/JCO.2008.16.5449. View

17.

Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J . Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer. 2014; 14:251. PMC: 3997215. DOI: 10.1186/1471-2407-14-251. View

18.

Li H, Wang C, Yu J, Cao S, Wei F, Zhang W . Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy. 2009; 11(8):1076-83. DOI: 10.3109/14653240903121252. View

19.

Jiang J, Wu C, Lu B . Cytokine-induced killer cells promote antitumor immunity. J Transl Med. 2013; 11:83. PMC: 3617047. DOI: 10.1186/1479-5876-11-83. View

20.

Ma Y, Xu Y, Tang L, Zhang Z, Wang J, Wang H . Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012; 1(1):11. PMC: 3514101. DOI: 10.1186/2162-3619-1-11. View